Medifast (MED) EPS (Weighted Average and Diluted) (2010 - 2026)

Medifast has reported EPS (Weighted Average and Diluted) for 17 years, with the latest figure at -$0.19 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 171.43% year-over-year to -$0.19; the trailing twelve-month figure through Mar 2026 stood at -$1.83 (down 181.54% YoY), and the FY2025 full-year result was -$1.7, down 994.74% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.19, up from -$1.65 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $3.67 in Q1 2023, with the low at -$1.65 in Q4 2025.
• Historically, EPS (Weighted Average and Diluted) has averaged $1.18 across 5 years, with a median of $0.55 in 2023.
• The largest YoY upside for EPS (Weighted Average and Diluted) was 129.33% in 2025 against a maximum downside of 2457.14% in 2025.
• Medifast's EPS (Weighted Average and Diluted) stood at $2.43 in 2022, then tumbled by 77.37% to $0.55 in 2023, then tumbled by 87.27% to $0.07 in 2024, then slumped by 2457.14% to -$1.65 in 2025, then surged by 88.48% to -$0.19 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.19 (Q1 2026), -$1.65 (Q4 2025), and -$0.21 (Q3 2025), per Business Quant data.